# A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

> **NCT05359393** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 52 (estimated)

## Conditions studied

- Advanced Rectal Cancer
- Liver Metastasis
- Pulmonary Metastasis
- Microsatellite Stable Colorectal Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** a combination therapy including tislelizumab

## Key facts

- **NCT ID:** NCT05359393
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359393, "A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05359393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*